Retatrutide and AOD-9604
No clinical trial has studied this combination. AOD-9604 failed to demonstrate significant weight loss in its own clinical trials. Retatrutide is not FDA approved. All rationale is anecdotal.
This page reviews what is known about combining retatrutide with AOD-9604: the regulatory status of each compound, what human evidence exists, theoretical rationale discussed in online communities, and the risks that are known or plausible.
What Each Compound Is
Why People Search for This Combination
Peptide communities discuss AOD-9604 with retatrutide for fat loss enhancement. AOD-9604 is marketed as a fat-burning peptide based on its structural similarity to the fat-mobilizing region of HGH. However, AOD-9604 failed to demonstrate significant weight loss compared to placebo in Phase 2/3 clinical trials, which significantly weakens the rationale for combining it with retatrutide.
Human Evidence
No published clinical trial has studied retatrutide combined with AOD-9604. AOD-9604 was studied in Phase 2/3 clinical trials for obesity and did not demonstrate significant weight loss compared to placebo. This clinical failure is a critical data point: the compound that communities discuss for fat loss enhancement has not demonstrated fat loss in controlled trials. Retatrutide's Phase 2 trial showed up to 24.2% mean weight loss at 48 weeks. No body composition data exists for the combination.
Theoretical Rationale
The theoretical rationale draws on AOD-9604's structural similarity to the lipolytic region of HGH. In animal models, AOD-9604 showed fat-mobilizing effects. However, these effects did not translate to significant weight loss in human clinical trials. The rationale for combining a clinically failed compound with retatrutide for enhanced fat loss is not supported by evidence.
Known and Plausible Risks
- Retatrutide: GI adverse events, heart rate increase, gallbladder effects, class-level precautions for thyroid C-cell tumors and pancreatitis
- AOD-9604: Human safety profile limited; failed to demonstrate significant weight loss in clinical trials; long-term effects unknown
- Combined: Unknown interaction risks; no safety data for the combination exists; AOD-9604 is not approved for human use
Body Composition Considerations
Retatrutide's Phase 2 data showed significant fat mass reduction. AOD-9604 did not demonstrate significant fat mass reduction in its own clinical trials. No body composition data exists for the combination. The clinical failure of AOD-9604 in obesity trials is a significant consideration when evaluating the rationale for this combination.
What People Are Discussing Online
Reddit communities (r/Peptides) discuss AOD-9604 with retatrutide for fat loss. Many users are unaware of AOD-9604's clinical trial failures. The compound continues to be marketed and discussed based on its theoretical mechanism rather than clinical evidence. These discussions are anecdotal.
Regulatory and Legal Context
AOD-9604 is not approved for human use. It is sold as a research chemical. Its clinical trial failures for obesity are a matter of public record. Retatrutide is not FDA approved. Using two unapproved or investigational compounds simultaneously outside a supervised clinical context carries significant legal and medical risks.
Frequently Asked Questions
No. No published clinical trial has studied this combination. AOD-9604 failed to demonstrate significant weight loss in its own clinical trials. No safety or efficacy data exists for the combination.
AOD-9604 was studied in Phase 2/3 clinical trials for obesity and did not demonstrate significant weight loss compared to placebo. This significantly weakens the rationale for combining it with retatrutide for fat loss.
AOD-9604 is not approved for human use. It is sold as a research chemical. Use of unapproved peptides carries unknown safety risks.
Ready to Start Your Physician Review?
$477 one-time payment. No membership. No recurring billing. No charge unless approved.
START PHYSICIAN REVIEW